BACKGROUND: Exacerbation is one of the most significant problems in patients with asthma. Although subpopulation of patients is more susceptible to exacerbations than others, which clinical features characterise susceptibility to exacerbation are not well understood. METHODS: Consecutive non-smoking adult patients with asthma who had multiple exacerbations (ME) despite regular maintenance treatment were compared with those who had at most single exacerbation as control during the previous 1 year. Exacerbation of asthma is defined initiations or escalations of systemic corticosteroid as part of the management for aggravated asthma condition. RESULTS: Patients with ME (n=32, male: 6, mean age: 46.7 years) were characterised by intensive current maintenance treatment (dose of inhaled corticosteroid; 1037.5+/-452.8 vs 621.6+/-257.3 microg, P=0.0005, proportion of oral corticosteroid users; 28.1% vs 2.7%, P=0.008), severe episodes of exacerbation (asthma-related hospitalisations; 71.9% vs 23.4%, P=0.0002, arrival on ambulance; 37.5% vs 8.1%, P=0.008), concomitant chronic sinusitis (34.4% vs 10.8%, P=0.038) and intolerance to non-steroidal anti-inflammatory drugs (NSAIDs) (34.4% vs 5.4%, P=0.006) in comparison with controls (n=37, male:11, mean age:44.4). Pulmonary function in patients with ME was characterised by persistent airflow limitation and reduced reversibility. CONCLUSION: Patients with ME are at increased risk for severe exacerbation despite more intensive maintenance anti-inflammatory treatment. Persistent irreversible airflow limitation and complications of chronic sinusitis and/or NSAIDs intolerance are characteristics to this subpopulation.
BACKGROUND: Exacerbation is one of the most significant problems in patients with asthma. Although subpopulation of patients is more susceptible to exacerbations than others, which clinical features characterise susceptibility to exacerbation are not well understood. METHODS: Consecutive non-smoking adult patients with asthma who had multiple exacerbations (ME) despite regular maintenance treatment were compared with those who had at most single exacerbation as control during the previous 1 year. Exacerbation of asthma is defined initiations or escalations of systemic corticosteroid as part of the management for aggravated asthma condition. RESULTS:Patients with ME (n=32, male: 6, mean age: 46.7 years) were characterised by intensive current maintenance treatment (dose of inhaled corticosteroid; 1037.5+/-452.8 vs 621.6+/-257.3 microg, P=0.0005, proportion of oral corticosteroid users; 28.1% vs 2.7%, P=0.008), severe episodes of exacerbation (asthma-related hospitalisations; 71.9% vs 23.4%, P=0.0002, arrival on ambulance; 37.5% vs 8.1%, P=0.008), concomitant chronic sinusitis (34.4% vs 10.8%, P=0.038) and intolerance to non-steroidal anti-inflammatory drugs (NSAIDs) (34.4% vs 5.4%, P=0.006) in comparison with controls (n=37, male:11, mean age:44.4). Pulmonary function in patients with ME was characterised by persistent airflow limitation and reduced reversibility. CONCLUSION:Patients with ME are at increased risk for severe exacerbation despite more intensive maintenance anti-inflammatory treatment. Persistent irreversible airflow limitation and complications of chronic sinusitis and/or NSAIDs intolerance are characteristics to this subpopulation.
Authors: Wendy C Moore; Eugene R Bleecker; Douglas Curran-Everett; Serpil C Erzurum; Bill T Ameredes; Leonard Bacharier; William J Calhoun; Mario Castro; Kian Fan Chung; Melissa P Clark; Raed A Dweik; Anne M Fitzpatrick; Benjamin Gaston; Mark Hew; Iftikhar Hussain; Nizar N Jarjour; Elliot Israel; Bruce D Levy; James R Murphy; Stephen P Peters; W Gerald Teague; Deborah A Meyers; William W Busse; Sally E Wenzel Journal: J Allergy Clin Immunol Date: 2007-02 Impact factor: 10.793
Authors: Rick Hodder; M Diane Lougheed; Brian H Rowe; J Mark FitzGerald; Alan G Kaplan; R Andrew McIvor Journal: CMAJ Date: 2009-10-26 Impact factor: 8.262
Authors: Loren C Denlinger; Brenda R Phillips; Sima Ramratnam; Kristie Ross; Nirav R Bhakta; Juan Carlos Cardet; Mario Castro; Stephen P Peters; Wanda Phipatanakul; Shean Aujla; Leonard B Bacharier; Eugene R Bleecker; Suzy A A Comhair; Andrea Coverstone; Mark DeBoer; Serpil C Erzurum; Sean B Fain; Merritt Fajt; Anne M Fitzpatrick; Jonathan Gaffin; Benjamin Gaston; Annette T Hastie; Gregory A Hawkins; Fernando Holguin; Anne-Marie Irani; Elliot Israel; Bruce D Levy; Ngoc Ly; Deborah A Meyers; Wendy C Moore; Ross Myers; Maria Theresa D Opina; Michael C Peters; Mark L Schiebler; Ronald L Sorkness; W Gerald Teague; Sally E Wenzel; Prescott G Woodruff; David T Mauger; John V Fahy; Nizar N Jarjour Journal: Am J Respir Crit Care Med Date: 2017-02-01 Impact factor: 21.405
Authors: David G Mummy; Katherine J Carey; Michael D Evans; Loren C Denlinger; Mark L Schiebler; Ronald L Sorkness; Nizar N Jarjour; Sean B Fain Journal: J Allergy Clin Immunol Date: 2020-03-13 Impact factor: 10.793
Authors: Nicole L Grossman; Victor E Ortega; Tonya S King; Eugene R Bleecker; Elizabeth A Ampleford; Leonard B Bacharier; Michael D Cabana; Juan C Cardet; Tara F Carr; Mario Castro; Loren C Denlinger; Joshua L Denson; Nicolas Fandino; Anne M Fitzpatrick; Gregory A Hawkins; Fernando Holguin; Jerry A Krishnan; Stephen C Lazarus; Sharmilee M Nyenhuis; Wanda Phipatanakul; Sima K Ramratnam; Sally Wenzel; Stephen P Peters; Deborah A Meyers; Michael E Wechsler; Elliot Israel Journal: J Allergy Clin Immunol Date: 2019-09-11 Impact factor: 10.793
Authors: Ka Pang Chan; Fanny Wai San Ko; Kwun Cheung Ling; Pik Shan Cheung; Lee Veronica Chan; Yu Hong Chan; Yi Tat Lo; Chun Kong Ng; Macy Mei-Sze Lui; Kwok Sang Wilson Yee; Cee Zhung Steven Tseng; Pak Yiu Tse; Mo Lin Maureen Wong; Kah Lin Choo; Wai Kei Lam; Chun Man Wong; Sheng Sheng Ho; Chung Tat Lun; Christopher Kei Wai Lai Journal: Immun Inflamm Dis Date: 2021-03-03